statistical programmer

• Develop targeted, study-specific SDTM and ADaM dataset checks
• Perform independent QC, from raw data to ADaM, of primary and key secondary endpoints
• Deliver programming results for ad-hoc analysis requests
• Collaborate with data management and their programming team to ensure appropriate data collection and reporting
• Participate in study team meeting and support statistician operational activities
• Assist in efforts to identify, develop, and implement departmental standards, applications, processes and training

We are seeking a statistical programmer to join our growing biometrics team to support clinical studies across Arrowhead’s expanding portfolio. This is an exciting opportunity for a candidate trained in statistical methods and analysis who has some or limited prior experience working as a statistical programmer. They will initially contribute their expertise in the area of statistical programming, with a goal to develop as a clinical trial statistician., * Master’s degree in Biostatistics/Statistics

• Basic understanding of clinical trials
• Working knowledge of SAS, including complex data manipulation and basic analysis procedures; or certifications for SAS programming
• Excellent verbal and written communication skills

Preferred

• Familiarity with CDISC standards, derivation of SDTM and ADaM specifications
• Simulations and sample size calculation
• Proficiency in R
• CRO experience

$90,000-$135,000 USD

Arrowhead provides competitive salaries and an excellent benefit package.

Arrowhead Pharmaceuticals, Inc. (Nasdaq ARWR) is a commercial stage biopharmaceutical company that develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The depth and versatility of our RNAi technologies enables us to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologics. Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver and lung with a promising pipeline of preclinical candidates.

Arrowhead’s corporate headquarters is in Pasadena, CA with research and development teams in Madison, WI & San Diego, CA, and a state of the art manufacturing facility in Verona, WI. Our employees are nimble, science-driven innovators who are collaborating to bring new therapies to patients in need.